Compare UNP & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNP | AZN |
|---|---|---|
| Founded | 1862 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1B | 316.4B |
| IPO Year | 2005 | N/A |
| Metric | UNP | AZN |
|---|---|---|
| Price | $272.32 | $185.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | ★ $275.55 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 1.7M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.08% | 1.73% |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $19,533,000,000.00 | N/A |
| Revenue This Year | $5.57 | $10.34 |
| Revenue Next Year | $4.29 | $6.43 |
| P/E Ratio | $91.74 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $214.32 | $68.62 |
| 52 Week High | $279.70 | $212.71 |
| Indicator | UNP | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 49.81 |
| Support Level | $218.81 | $180.98 |
| Resistance Level | $272.40 | $191.50 |
| Average True Range (ATR) | 6.88 | 3.00 |
| MACD | -0.72 | -0.05 |
| Stochastic Oscillator | 64.26 | 61.27 |
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24.5 billion of revenue in 2025 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.